|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: a clinical review. JAMA. 310:1842–1850.
2013.
|
|
2
|
Iwamoto FM and Fine HA: Bevacizumab for
malignant gliomas. Arch Neurol. 67:285–288. 2010.
|
|
3
|
Reardon DA, Desjardins A, Peters K, et al:
Phase II study of metronomic chemotherapy with bevacizumab for
recurrent glioblastoma after progression on bevacizumab therapy. J
Neurooncol. 103:371–379. 2011.
|
|
4
|
Liu XM, Zhang QP, Mu YG, et al: Clinical
significance of vasculogenic mimicry in human gliomas. J
Neurooncol. 105:173–179. 2011.
|
|
5
|
Wang SY, Yu L, Ling GQ, et al:
Vasculogenic mimicry and its clinical significance in
medulloblastoma. Cancer Biol Ther. 13:341–348. 2012.
|
|
6
|
Chen Y, Jing Z, Luo C, Zhuang M, Xia J,
Chen Z and Wang Y: Vasculogenic mimicry-potential target for
glioblastoma therapy: an in vitro and in vivo study. Med Oncol.
29:324–331. 2012.
|
|
7
|
Hess AR, Seftor EA, Gardner LM, et al:
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine
phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer
Res. 61:3250–3255. 2001.
|
|
8
|
Seftor RE, Seftor EA, Koshikawa N, et al:
Cooperative interactions of laminin 5 gamma2 chain, matrix
metalloproteinase-2, and membrane type-1-matrix/metalloproteinase
are required for mimicry of embryonic vasculogenesis by aggressive
melanoma. Cancer Res. 61:6322–6327. 2001.
|
|
9
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.
|
|
10
|
Paulis YW, Soetekouw PM, Verheul HM,
Tjan-Heijnen VC and Griffioen AW: Signalling pathways in
vasculogenic mimicry. Biochim Biophys Acta. 1806:18–28. 2010.
|
|
11
|
Kirschmann DA, Seftor EA, Hardy KM, et al:
Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic
and therapeutic implications. Clin Cancer Res. 18:2726–2732.
2012.
|
|
12
|
Li L, Aggarwal BB, Shishodia S, Abbruzzese
J and Kurzrock R: Nuclear factor-kappaB and IkappaB kinase are
constitutively active in human pancreatic cells, and their
down-regulation by curcumin (diferuloylmethane) is associated with
the suppression of proliferation and the induction of apoptosis.
Cancer. 101:2351–2362. 2004.
|
|
13
|
Sharma RA, Gescher AJ and Steward WP:
Curcumin: the story so far. Eur J Cancer. 41:1955–1968. 2005.
|
|
14
|
Singh S and Khar A: Biological effects of
curcumin and its role in cancer chemoprevention and therapy.
Anticancer Agents Med Chem. 6:259–270. 2006.
|
|
15
|
Das T, Sa G, Saha B and Das K: Multifocal
signal modulation therapy of cancer: ancient weapon, modern
targets. Mol Cell Biochem. 336:85–95. 2010.
|
|
16
|
Chen LX, He YJ, Zhao SZ, et al: Inhibition
of tumor growth and vasculogenic mimicry by curcumin through
down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal
melanoma model. Cancer Biol Ther. 11:229–235. 2011.
|
|
17
|
Ling G, Wang S, Song Z, et al:
Transforming growth factor-β is required for vasculogenic mimicry
formation in glioma cell line U251MG. Cancer Biol Ther. 12:978–988.
2011.
|
|
18
|
Senft C, Polacin M, Priester M, Seifert V,
Kögel D and Weissenberger J: The nontoxic natural compound Curcumin
exerts anti-proliferative, anti-migratory, and anti-invasive
properties against malignant gliomas. BMC Cancer. 10:4912010.
|
|
19
|
Weissenberger J, Priester M, Bernreuther
C, Rakel S, Glatzel M, Seifert V and Kögel D: Dietary curcumin
attenuates glioma growth in a syngeneic mouse model by inhibition
of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res.
16:5781–5795. 2010.
|
|
20
|
Su CC, Wang MJ and Chiu TL: The
anti-cancer efficacy of curcumin scrutinized through core signaling
pathways in glioblastoma. Int J Mol Med. 26:217–224. 2010.
|
|
21
|
Aoki H, Takada Y, Kondo S, Sawaya R,
Aggarwal BB and Kondo Y: Evidence that curcumin suppresses the
growth of malignant gliomas in vitro and in vivo through induction
of autophagy: role of Akt and extracellular signal-regulated kinase
signaling pathways. Mol Pharmacol. 72:29–39. 2007.
|
|
22
|
Zanotto-Filho A, Braganhol E, Edelweiss
MI, et al: The curry spice curcumin selectively inhibits cancer
cells growth in vitro and in preclinical model of glioblastoma. J
Nutr Biochem. 23:591–601. 2012.
|
|
23
|
Rekers NH, Sminia P and Peters GJ: Towards
tailored therapy of glioblastoma multiforme. J Chemother.
23:187–199. 2011.
|
|
24
|
Chatterjee S and Bhattacharjee B: Use of
natural molecules as anti-angiogenic inhibitors for vascular
endothelial growth factor receptor. Bioinformation. 8:1249–1254.
2012.
|
|
25
|
Gururaj AE, Belakavadi M, Venkatesh DA,
Marmé D and Salimath BP: Molecular mechanisms of anti-angiogenic
effect of curcumin. Biochem Biophys Res Commun. 297:934–942.
2002.
|
|
26
|
Kim SY, Jung SH and Kim HS: Curcumin is a
potent broad spectrum inhibitor of matrix metalloproteinase gene
expression in human astroglioma cells. Biochem Biophys Res Commun.
337:510–516. 2005.
|
|
27
|
Perry MC, Demeule M, Régina A, Moumdjian R
and Béliveau R: Curcumin inhibits tumor growth and angiogenesis in
glioblastoma xenografts. Mol Nutr Food Res. 54:1192–1201. 2010.
|
|
28
|
Han L, Yang Y, Yue X, et al: Inactivation
of PI3K/AKT signaling inhibits glioma cell growth through
modulation of β-catenin-mediated transcription. Brain Res.
1366:9–17. 2010.
|
|
29
|
Kwiatkowska A, Kijewska M, Lipko M, Hibner
U and Kaminska B: Downregulation of Akt and FAK phosphorylation
reduces invasion of glioblastoma cells by impairment of MT1-MMP
shuttling to lamellipodia and downregulates MMPs expression.
Biochim Biophys Acta. 1813:655–667. 2011.
|
|
30
|
Huang HP, Shih YW, Wu CH, et al:
Inhibitory effect of penta-acetyl geniposide on C6 glioma cells
metastasis by inhibiting matrix metalloproteinase-2 expression
involved in both the PI3K and ERK signaling pathways. Chem Biol
Interact. 181:8–14. 2009.
|
|
31
|
Wu N, Zhao X, Liu M, et al: Role of
microRNA-26b in glioma development and its mediated regulation on
EphA2. PLoS One. 6:e162642011.
|
